Project List
List projects.
Fields
id (integer)
Primary key.
Expansions
To activate relation expansion add the desired fields as a comma separated
list to the expand query parameter like this:
?expand=<field>,<field>,<field>,...
The following relational fields can be expanded:
organizationcategorytypepartner_functionmanagercontactstatusgrantresearcheventstudylanguageprogramfunders
Filters
To filter for exact value matches:
?<fieldname>=<value>
Possible exact filters:
organizationcategorymanagercontactstatusgrantresearchstudylanguagefundersprogram
For advanced filtering use lookups:
?<fieldname>__<lookup>=<value>
All fields with advanced lookups can also be used for exact value matches as described above.
Possible advanced lookups:
begin_planned:gt,gte,lt,ltebegin_effective:gt,gte,lt,lteend_planned:gt,gte,lt,lteend_effective:gt,gte,lt,lte
GET /v1/research/project/?format=api&offset=580&ordering=-begin_planned
{ "count": 2265, "next": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=600&ordering=-begin_planned", "previous": "https://api-test.medunigraz.at/v1/research/project/?format=api&limit=20&offset=560&ordering=-begin_planned", "results": [ { "id": 7490, "title": { "de": "NR4A1 mediierte Regulation der Immuneevasion in Lymphomen", "en": "NR4A1-mediated regulation of immune evasion in lymphoma*" }, "short": "NIEL", "url": null, "abstract": { "de": "Tumorzellen haben eine Reihe von Mechanismen entwickelt, um die immunvermittelte Erkennung und Zerstörung von Tumorzellen zu umgehen bzw. zu unterdrücken. Eine unserer Erkenntnisse ist, dass ein Teil der aggressiven B-Lymphome, maligne Tumore der antikörperproduzierenden Zellen, eine geringe Expression des Transkriptionsfaktors NR4A1 aufweisen. NR4A1 reguliert, wie andere Transkriptionsfaktoren, zahlreiche biologische Prozesse in Zellen. Die Funktion in aggressiven B-Lymphomen ist jedoch bis dato noch nicht untersucht worden. In unserer Vorstudie haben wir herausgefunden, dass eine niedrige NR4A1-Expression mit einer reduzierten Überlebensrate bei Standardtherapie einherging. In unserem Lymphommausmodell konnten wir nachweisen, dass der Verlust von Nr4a1 die Lymphomentwicklung deutlich beschleunigte, begleitet von einer erhöhten Expression immunsuppressiver Oberflächenmoleküle und einem höheren Gehalt an Immunzellen in Mäusen, die ein funktionierendes Immunsystem besaßen, aber nicht in Mausmodellen mit einem nicht funktionierenden Immunsystem. Weitere Analysen deuten darauf hin, dass der Verlust von Nr4a1 mit einer verminderten immunzellvermittelten Zerstörung von Lymphomzellen verbunden ist. Zusammenfassend deuten unsere Daten auf eine tumorsuppressive Funktion von NR4A1 hin, die durch immunregulatorische Eigenschaften bei der Entwicklung aggressiver Lymphome vermittelt wird.\r\nIn dem geplanten Projekt wollen wir mit globalen genetischen Ansätzen aufklären, welche Gene und/oder genetischen Programme durch NR4A1 reguliert werden, sowie mit Hilfe neuartiger Sequenzierungstechnologien die Auswirkungen von NR4A1 auf die Zusammensetzung und die Aktivität der Immunzellen in aggressiven Lymphomen untersuchen. Darüber hinaus wollen wir die Wirksamkeit von Immuntherapien als Einzelwirkstoffe sowie in Kombination (einschließlich neuer Moleküle) in Bezug auf die NR4A1-Expression bei aggressiven Lymphomen funktionell testen. Schließlich werden wir die Daten aus dem präklinischen Modell auf Patientenproben übertragen. Hier werden wir NR4A1, Antigenpräsentation und immunsuppressive Oberflächenmoleküle in unserer DLBCL-Patientenkohorte untersuchen, um unsere Erkenntnisse in einem klinischeren Umfeld zu validieren.\r\nAnhand der Ergebnisse könnten wir einen neuen Mechanismus identifizieren, der wesentlich zur Lymphomentwicklung beiträgt und zur Identifizierung von Lymphompatienten genutzt werden kann, die von einer neuartigen Immuntherapie profitieren könnten.\r\n", "en": "Tumour cells have developed a number of mechanisms to avoid or suppress their recognition, targeting and killing by immune cells. We found out that a part of aggressive B cell lymphomas, a tumour consisting of the antibody-producing cells, exhibited low expression of the transcription factor NR4A1. NR4A1, like other transcription factors, regulates numerous biological processes in cells. However, its function has not been yet investigated in aggressive B cell lymphomas. In our preliminary study, we observed that low NR4A1 levelwas associated with reduced survival in patients treated with standard therapy. In mice with a functional immune system, we showed that loss of Nr4a1 markedly accelerated the development of lymphoma, with increased presence of surface molecules that inhibit immune cells, but also a higher content of these immune cells compared to immunodeficient mouse models. Further, our analyses indicate that loss of Nr4a1 is linked to reduced killing of lymphoma by immune cells. Taken together our data indicate a tumour-suppressive function of NR4A1 mediated by its immune regulatory properties in the development of aggressive lymphomas.\r\nIn the planned project, we aim to elucidate which genes and/or genetic programs are regulated by NR4A1 with global genetic approaches and to investigate the impact of NR4A1 on immune cell composition and activity in aggressive lymphomas using novel sequencing technologies. In addition, our aim is to functionally test the efficacy of immune therapies as single agents as well as in combination (including novel molecules) in relation to the NR4A1 level in aggressive lymphomas. Finally, we will transfer data from the preclinical model to patients samples and investigate NR4A1 expression, antigen presentation, and immune suppressive surface molecules in our DLBCL patient cohort to validate our findings in a more clinical setting.\r\nBased on the finding, we might identify a novel mechanism, which significantly contribute to lymphoma development and which can be used to identify lymphoma patients who may benefit from a novel type of immune therapy. \r\n" }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-05-15T02:00:00+02:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-10-14T02:00:00+02:00", "assignment": "2023-04-11T15:10:20+02:00", "program": null, "subprogram": null, "organization": 14082, "category": 10, "type": 10, "partner_function": 4, "manager": 59183, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P36643", "ethics_committee": null, "edudract_number": null, "persons": [ "7490-100134-12", "7490-59183-10", "7490-79614-12", "7490-82501-12", "7490-85928-12", "7490-111069-12", "7490-130555-12", "7490-131900-12", "7490-122350-12", "7490-122590-12" ] }, { "id": 7271, "title": { "de": "DIOPTRA - Früherkennung von neuen Initiationsmechanismus-Protein-Biomarkern bei Darmkrebs ", "en": "DIOPTRA - Early Dynamic Screening for Colorectal Cancer via Novel Protein Biomarkers Reflecting Biological Initiation Mechanisms" }, "short": "DIOPTRA", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2026-12-31T01:00:00+01:00", "end_effective": "2026-12-31T01:00:00+01:00", "assignment": "2022-11-29T13:54:01+01:00", "program": 219, "subprogram": null, "organization": 28392, "category": 10, "type": 10, "partner_function": 4, "manager": 98966, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101096649", "ethics_committee": null, "edudract_number": null, "persons": [ "7271-98966-10" ] }, { "id": 7403, "title": { "de": "Die Rolle der Nekroptose in der akuten myeloischen Leukämie", "en": "The role of necroptosis in acute myeloid leukemia" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2024-12-31T01:00:00+01:00", "end_effective": "2024-12-31T01:00:00+01:00", "assignment": "2023-02-16T11:30:10+01:00", "program": 207, "subprogram": null, "organization": 14085, "category": 10, "type": 10, "partner_function": 1, "manager": 107132, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 20 ], "funder_projectcode": "SI 19/2023", "ethics_committee": null, "edudract_number": null, "persons": [ "7403-107132-10", "7403-111910-12" ] }, { "id": 7288, "title": { "de": "Früherkennung von Bauchspeicheldrüsenkrebsg durch Liquid biopsies", "en": "PANcreatic CAncer Initial Detection via liquid biopsy\r\n" }, "short": "PANCAID", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2027-12-30T01:00:00+01:00", "end_effective": "2027-12-31T01:00:00+01:00", "assignment": "2022-12-05T10:24:50+01:00", "program": 219, "subprogram": null, "organization": 14021, "category": 10, "type": 10, "partner_function": 2, "manager": 50899, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101096309", "ethics_committee": null, "edudract_number": null, "persons": [ "7288-50899-10", "7288-76215-12", "7288-120331-12", "7288-121409-12" ] }, { "id": 7253, "title": { "de": "A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways", "en": "A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways" }, "short": "ONCOSCREEN", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2026-12-31T01:00:00+01:00", "end_effective": "2026-12-31T01:00:00+01:00", "assignment": "2022-11-16T10:41:30+01:00", "program": 219, "subprogram": null, "organization": 14020, "category": 10, "type": 10, "partner_function": 2, "manager": 99976, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101097036", "ethics_committee": null, "edudract_number": null, "persons": [ "7253-99976-10", "7253-100172-12", "7253-108575-12", "7253-119108-12", "7253-133280-12" ] }, { "id": 7252, "title": { "de": "Integration von Bewegung und NAD+ zur Verringerung des kardiometabolischen Risikos", "en": "Integrating exercise and NAD+ to reduce cardiometabolic risk" }, "short": "INTERACD+ BioTechMed Flagship 2022", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-03-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2027-02-28T01:00:00+01:00", "assignment": "2022-11-16T10:02:31+01:00", "program": null, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 3, "manager": 60041, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2325 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7252-60041-10", "7252-75758-12", "7252-94512-12", "7252-108473-12", "7252-114514-12", "7252-119109-12", "7252-122750-12" ] }, { "id": 7335, "title": { "de": "Entwicklung neuer Screeningverfahren von Anti-Aging Wirkstoffen in fluoreszierenden Fadenwürmern", "en": "Development of new screening methods to analyze anti-aging compounds in fluorescent nematodes" }, "short": "WormScreen", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2023-12-31T01:00:00+01:00", "end_effective": "2023-12-31T01:00:00+01:00", "assignment": "2023-01-17T13:50:34+01:00", "program": null, "subprogram": null, "organization": 14013, "category": 10, "type": 10, "partner_function": 4, "manager": 85069, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2471 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7335-85069-10" ] }, { "id": 7308, "title": { "de": "CBmed: 2.22B - Next generation drug screening platform for precision oncology services ", "en": "CBmed: 2.22B - Next generation drug screening platform for precision oncology services " }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2019-01-01T01:00:00+01:00", "end_planned": "2023-12-31T01:00:00+01:00", "end_effective": "2023-12-31T01:00:00+01:00", "assignment": "2022-12-19T13:13:31+01:00", "program": null, "subprogram": null, "organization": 14080, "category": 10, "type": 10, "partner_function": 4, "manager": 56667, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 416 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7308-56667-10" ] }, { "id": 7215, "title": { "de": "Die Bedeutung von \"Glial Fibrillary Acidic Pretein\" im Plasma als diagnostischer und prognostischer Marker der Hirnalterung und der Alzheimer Krankheit", "en": "The Role of Plasma Glial Fibrillary Acidic Protein as a diagnostic and prognostic marker in brain aging and Alzheimer´s disease" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2025-12-31T01:00:00+01:00", "assignment": "2022-10-13T14:04:13+02:00", "program": null, "subprogram": null, "organization": 14051, "category": 10, "type": 10, "partner_function": 4, "manager": 57435, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2269 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7215-57435-10", "7215-73547-11" ] }, { "id": 7306, "title": { "de": "KCNRG in der Regulation der Lungenzirkulation", "en": "Novel role of the potassium channel regulator KCNRG in the pulmonary circulation" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-07-01T02:00:00+02:00", "end_planned": "2026-12-31T01:00:00+01:00", "end_effective": "2027-06-30T02:00:00+02:00", "assignment": "2022-12-19T11:45:25+01:00", "program": 111, "subprogram": null, "organization": 14006, "category": 10, "type": 10, "partner_function": 4, "manager": 54345, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "I 6299", "ethics_committee": null, "edudract_number": null, "persons": [ "7306-62906-12", "7306-84366-12", "7306-91409-12", "7306-102187-12", "7306-110870-12", "7306-54345-10" ] }, { "id": 7190, "title": { "de": "Was macht Albumin (in)effektiv?", "en": "What makes albumin (in)effective?" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2023-01-31T01:00:00+01:00", "end_effective": "2025-11-07T01:00:00+01:00", "assignment": "2022-09-28T11:32:05+02:00", "program": null, "subprogram": null, "organization": 14012, "category": 10, "type": 10, "partner_function": 4, "manager": 90044, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2623 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7190-90044-10" ] }, { "id": 7710, "title": { "de": "Metabolomics bei PH: Erkennung und Risikovorhersage", "en": "Metabolomics in PH: detection, risk prediction, monitoring" }, "short": "GRAPH-M", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2024-04-01T02:00:00+02:00", "end_planned": "2027-12-31T01:00:00+01:00", "end_effective": "2028-03-31T02:00:00+02:00", "assignment": "2023-08-08T13:40:35+02:00", "program": 108, "subprogram": null, "organization": 14006, "category": 10, "type": 10, "partner_function": 4, "manager": 54345, "contact": null, "status": 2, "research": 4, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "KLI 1153", "ethics_committee": null, "edudract_number": null, "persons": [ "7710-91409-12", "7710-73404-12", "7710-115981-12", "7710-54345-10" ] }, { "id": 7549, "title": { "de": "FXR Leber-Fett Achse", "en": "FXR liver adipose axis" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-11-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2027-10-31T02:00:00+02:00", "assignment": "2023-05-09T13:15:51+02:00", "program": 72, "subprogram": null, "organization": 14081, "category": 10, "type": 10, "partner_function": 4, "manager": 57377, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "P36543", "ethics_committee": null, "edudract_number": null, "persons": [ "7549-50626-12", "7549-54247-12", "7549-57377-10", "7549-111969-12", "7549-123430-12" ] }, { "id": 7327, "title": { "de": "Sichere Entlassung aus dem Krankenhaus durch sichere Information (GO-SAFE 2.0)", "en": "Safe discharge from the hospital through safe information (GO-SAFE 2.0)" }, "short": " GO-SAFE 2.0", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2024-12-31T01:00:00+01:00", "end_effective": "2024-12-31T01:00:00+01:00", "assignment": "2023-01-10T17:35:46+01:00", "program": null, "subprogram": null, "organization": 14076, "category": 10, "type": 10, "partner_function": 3, "manager": 92002, "contact": null, "status": 2, "research": 2, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2160 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7327-92002-10" ] }, { "id": 7520, "title": { "de": "Isoformen der Pyruvatkinase als neue Biomarker und therapeutische Ziele bei Multipler Sklerose", "en": "Pyruvate kinase isoforms as novel biomarkers\r\nand therapeutic targets in multiple sclerosis\r\n" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-05-01T02:00:00+02:00", "end_planned": "2023-12-31T01:00:00+01:00", "end_effective": "2024-04-30T02:00:00+02:00", "assignment": "2023-04-19T16:13:39+02:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": 107391, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2471 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7520-57435-12", "7520-107391-10" ] }, { "id": 7309, "title": { "de": "Bewertung der Rolle der Succinat-Sensierung über GPR91 bei der T-Zell-vermittelten Anti-Tumor-Immunität ", "en": "Evaluating the role of succinate sensing via GPR91 in T cell-mediated \r\nanti-tumour immunity " }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-03-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-09-30T02:00:00+02:00", "assignment": "2022-12-20T13:44:44+01:00", "program": null, "subprogram": null, "organization": 14014, "category": 10, "type": 10, "partner_function": 4, "manager": 107391, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2576 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7309-60706-12", "7309-107391-10" ] }, { "id": 7191, "title": { "de": "ELPHI: ElektroPHoretische Implantate für steuerbare Chemotherapie von Gehirntumoren", "en": "ELPHI: ElektroPHoretic Implants for Controlled Chemotherapy of Brain Tumors" }, "short": "ELPHI", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2023-12-31T01:00:00+01:00", "end_effective": "2024-03-31T01:00:00+01:00", "assignment": "2022-09-29T18:00:07+02:00", "program": null, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 4, "manager": 99703, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 135 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7191-99703-10" ] }, { "id": 7227, "title": { "de": "Erforschung neuer Biomarker zur Früherkennung von Transplantatabstoßung", "en": "Novel Biomarker for the detection of heart transplant rejection" }, "short": null, "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-01-01T01:00:00+01:00", "end_planned": "2024-12-31T01:00:00+01:00", "end_effective": "2027-12-31T01:00:00+01:00", "assignment": "2022-10-21T11:29:34+02:00", "program": null, "subprogram": null, "organization": 14083, "category": 10, "type": 10, "partner_function": 3, "manager": 72301, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 2801 ], "funder_projectcode": null, "ethics_committee": null, "edudract_number": null, "persons": [ "7227-60377-12", "7227-72301-10", "7227-91265-12", "7227-101322-12", "7227-110289-12" ] }, { "id": 7363, "title": { "de": "Digitale Zwillinge für die Behandlung von Vorhofflimmern", "en": "Digital Twins to Treat Atrial Fibrillation" }, "short": "DAWN-AF", "url": null, "abstract": { "de": "Vorhofflimmern (VHF) ist die häufigste Arrhythmie des Herzens. Bei VHF handelt es sich um eine fortschreitende Erkrankung des Herzens. Je länger VHF andauert, umso schwieriger ist die Behandlung, und das Risiko Folgeschäden wie Schlaganfälle, Demenz oder Herzinsuffizienz zu erleiden nimmt zu. Die effektivste Therapie für VHF ist die Ablationstherapie mittels Herzkatheter, eine Prozedur, bei der Gewebe in den Vorhöfen des Herzens zerstört wird um die Ausbreitungspfade von elektrischen Wellen einzuschränken. Aktuelle Therapieformen sind generisch, die Variabilität der Patienten hinsichtlich der Struktur der Vorhöfe wird nicht berücksichtigt, weshalb VHF-Symptome auch nach anfänglich positiver Therapie häufig zurückkehren.\r\n\r\nDas Ziel des DAWN-AF Projektes ist es, einen personalisierten medizinischen Ansatz zu entwickeln, der auf Computermodellierung basiert. Konkret werden digitale Zwillinge der Vorhöfe des Herzens entwickelt. Diese können zur verbesserten Planung der VHF-Ablation im Computer verwendet werden, um ein Wiederauftreten von VHF zu verhindern. Dazu werden präoperative Messungen wie das Elektrokardiogramm und tomographische Bildgebung (MRT/CT) verwendet, um anatomisch und funktionell detaillierte digitale Zwillinge zu erstellen. Da diese Daten jedoch nicht ausreichen, um die Vorhöfe eindeutig zu charakterisieren, wird für jeden Patienten ein Satz an potenziellen digitalen Zwillingen erstellt, um dann für jede einzelne Variation die jeweils ideale Ablationsbehandlung zu bestimmen. Anhand von invasiven Messungen während des Eingriffs wird dann derjenige digitale Zwilling ausgewählt, der am besten zum Patienten passt. Eine wirtschaftliche Analyse der VHF-Therapie wird den Nutzen unseres mittels digitaler Zwillinge personalisierten Therapiezugangs bewerten. Dieser Nutzen ergibt sich aus einer frühzeitigen präventiven Behandlung, aus einem länger anhaltenden Therapieerfolg, aus einer verkürzten Eingriffsdauer und einer Reduktion des Eingriffsrisikos.\r\n", "en": "Atrial Fibrillation (AF) is the most common cardiac arrhythmia. Since AF is progressive, the longer one has it, the harder it is to treat, and the risks of stroke, dementia and heart failure increase. The most effective treatment is catheter ablation therapy, a procedure that strategically destroys tissue to restrict propagation of electrical waves. However, approaches are currently generic, ignoring patient variability in atrial structure, and AF usually recurs. We aim to develop a personalised medicine approach based on computer modelling, to use digital twins to plan AF ablation to prevent recurrence. We propose to use preoperative measurements, imaging (MRI/CT) and the ECG, to build digital twins. However, these data are insufficient to uniquely characterize the atria, so we will build sets of potential digital twins for each patient, each of which will have its ideal ablation treatment determined. Invasive measurements acquired during the ablation procedure will be then used to select the digital twin that best matches the patient. Economic analysis will evaluate benefits arising from early preventative and longer-lasting treatment, reduced duration and procedural risks of interventions." }, "begin_planned": "2023-01-01T01:00:00+01:00", "begin_effective": "2023-03-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2026-09-28T02:00:00+02:00", "assignment": "2023-02-01T16:15:05+01:00", "program": 112, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 50966, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 9 ], "funder_projectcode": "I 6476-B", "ethics_committee": null, "edudract_number": null, "persons": [ "7363-50966-10", "7363-91352-12", "7363-96212-12", "7363-50967-12", "7363-122514-12" ] }, { "id": 7407, "title": { "de": "Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics", "en": "Bioorthogonal Implantable Iontronic Switch to Temporally Control the Local Release of Chemotherapeutics" }, "short": "bioSWITCH", "url": null, "abstract": { "de": null, "en": null }, "begin_planned": "2022-12-01T01:00:00+01:00", "begin_effective": "2023-03-01T01:00:00+01:00", "end_planned": "2025-12-31T01:00:00+01:00", "end_effective": "2027-02-28T01:00:00+01:00", "assignment": "2023-02-17T11:53:05+01:00", "program": 218, "subprogram": null, "organization": 14011, "category": 10, "type": 10, "partner_function": 2, "manager": 98848, "contact": null, "status": 2, "research": 1, "grant": 10, "event": null, "study": null, "language": null, "funders": [ 10 ], "funder_projectcode": "101099963", "ethics_committee": null, "edudract_number": null, "persons": [ "7407-99703-11", "7407-57129-12", "7407-98848-10", "7407-107229-12", "7407-114534-12", "7407-119850-12", "7407-122232-12" ] } ] }